Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DF-Crefmirlimab PET in Locally Advanced or Metastatic Solid Tumours
NCT06534190Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2025
- Primary completion
- Nov 2028
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of [89Zr]Zr-Df-Crefmirlimab in solid tumor, sponsored by University Medical Center Groningen. Started Mar 2025; status: recruiting.
02
Drugs
[89Zr]Zr-Df-Crefmirlimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06534190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534190.